Merck Tops 2023 Global Pharma R&D Spending Ranking, Overtaking Roche

Mar 29, 2024 08:08 CST Updated 08:08

Johnson & Johnson

Medical Device R&D and Manufacturer

Recently, FIERCE Biotech releasedTop 10 Global Pharmaceutical Companies by R&D Investment in 2023, respectivelyMerck & Co.（Merck & Co.）、Johnson & Johnson（Johnson & Johnson）、Roche（Roche）、Novartis（Novartis）、AstraZeneca（AstraZeneca）、Pfizer Inc.（Pfizer）、Eli Lilly and Company（Eli Lilly）、Bristol-Myers Squibb（Bristol Myers Squibb）、AbbVie（AbbVie）、Sanofi（Sanofi）。

Compared with 2022, the list of pharmaceutical companies has not changed, only the ranking order has. After being at the top for nearly 10 years,Roche（Roche）Finally fell from the top position in annual R&D investment,Merck & Co.（Merck & Co.）With R&D investment exceeding 30 billion USD, it has topped the list for the first time.

2023 was a year full of changes and adjustments. COVID-19 gradually faded from the forefront of the pharmaceutical industry, while new weight-loss drugs, GLP-1 receptor agonists, took center stage. For years, they have occupied the top position in R&D investment.Roche（Roche）In this year, byMerck & Co.（Merck & Co.）AndJohnson & Johnson（Johnson & Johnson）Surpassing to rank only third.

Merck & Co.

Ranking: First

R&D Budget: $30.53 Billion

Change compared to 2022: 126%

Total Revenue in 2023: $60.1 billion

R&D Budget as a Percentage of Revenue: 50.8%

Merck reported full-year R&D expenses of up to $30.5 billion in 2023, with R&D expenses accounting for more than 50% of revenue, far higher than its $13.5 billion in 2022. This amount is obviously very exaggerated. In fact, more than half of the $30.5 billion was related to deals, including an investment of $5.5 billion inDaiichi SankyoCollaborative Development of ADC Drugs, Investing $11.4 Billion in AcquisitionPrometheusAndImago BiosciencesIf the funds invested in collaborations and acquisitions are excluded, its R&D expenditure in 2023 will drop to $13.6 billion, only $1 billion more than in 2022.

Johnson & Johnson

Ranking: Second

R&D Budget: $15.1 Billion

Change from 2022: 6.7%

Total Revenue in 2023: $85.2 billion

R&D Budget as a Percentage of Revenue: 17.7%

Roche

Ranking: Third

R&D Budget: $14.97 billion

Change compared to 2022: -5.7%

Total Revenue in 2023: $66.4 Billion

R&D budget as a percentage of revenue: 22.6%

Novartis

Ranking: Fourth

R&D Budget: $11.37 billion

Change compared to 2022: 23.9%
Total Revenue in 2023: $45.4 billion
R&D Budget as a Percentage of Revenue: 25%

AstraZeneca

Ranking: Fifth

R&D Budget: $10.94 billion
Change compared to 2022: 12%
Total Revenue in 2023: 45.81 billion USD
R&D Budget as a Percentage of Revenue: 24%

Pfizer Inc.

Ranking: Sixth

R&D Budget: $10.67 Billion
Change compared to 2022: -6.65%
Total Revenue in 2023: $58.5 Billion
R&D budget as a percentage of revenue: 18.2%

Eli Lilly and Company

Ranking: Seventh

R&D Budget: $9.31 billion
Change from 2022: 29%
Total Revenue in 2023: $34.12 billion
R&D Budget as a Percentage of Revenue: 27%

Bristol-Myers Squibb

Ranking: Eighth

R&D Budget: $9.29 billion
Change compared to 2022: -2.22%
Total Revenue in 2023: $45 billion
R&D Budget as a Percentage of Revenue: 20.6%

AbbVie

Ranking: Ninth

R&D Budget: $7.68 Billion
Change from 2022: 18%
Total Revenue in 2023: $54.32 Billion
R&D Budget as a Percentage of Revenue: 14.1%

Sanofi

Ranking: 10th

R&D Budget: $7.32 billion
Change from 2022: 3%
Total Revenue in 2023: $46.81 Billion
Percentage of R&D budget to revenue: 15.6%

Reference link: https://www.fiercebiotech.com/biotech/top-10-pharma-rd-budgets-2023

JoinPharm陌VIP Dry Goods Shop Get the latest dry goods resources

Disclaimer: If there are articles that are reprinted and shared, the views, content, and images of the articles belong to the original authors. If there are any issues related to infringement, please contact us for removal!

Scan the QR code to follow us

Image Source: Internet

Typesetting: Yao Mo